Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

11 Jan 2019

Abstract excerpt

KIT D816 mutations ( KIT D816 mut ) are strongly associated with systemic mastocytosis (SM) but are also detectable in acute myeloid leukemia (AML), where they represent an adverse prognostic factor in combination with core binding factor (CBF) fusion genes. Here, we evaluated the clinical and molecular features of KIT D816 mut /CBF-negative (CBF neg ) AML, a previously uncharacterized combination. All KIT D816...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to Mast cells and histamine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30635631
DOI: 10.1038/s41375-018-0346-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosisPMID 30635631Read ↗

Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic MastocytosisSemantic proximity Read ↗

Myeloid neoplasms with mutated KIT: comparative clinicopathologic analysis of D816 vs. non-D816 variants.Semantic proximity Read ↗

Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.Semantic proximity Read ↗

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.Semantic proximity Read ↗

Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock.Semantic proximity Read ↗

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.Semantic proximity Read ↗

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.Semantic proximity Read ↗

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.Semantic proximity Read ↗

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.Semantic proximity Read ↗

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).Semantic proximity Read ↗

Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.